XML 154 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 1,975 $ 1,782
Accounts receivables 5,676 5,822
Inventories 4,422 4,731
Prepaid expenses 870 899
Other current assets 434 468
Assets held for sale 87 92
Total current assets 13,464 13,794
Deferred income taxes 386 368
Other non-current assets 591 731
Property, plant and equipment, net 6,436 6,868
Operating lease right-of-use assets 514  
Identifiable intangible assets, net 11,232 14,005
Goodwill [1] 24,846 24,917
Total assets 57,470 60,683
Current liabilities:    
Short-term debt 2,345 2,216
Sales reserves and allowances 6,159 6,711
Accounts payables 1,718 1,853
Employee-related obligations 693 870
Accrued expenses 1,869 1,868
Other current liabilities 889 804
Total current liabilities 13,674 14,322
Long-term liabilities:    
Deferred income taxes 1,096 2,140
Other taxes and long-term liabilities 2,640 1,727
Senior notes and loans 24,562 26,700
Operating lease liabilities 435  
Total long-term liabilities 28,733 30,567
Commitments and contingencies, see note 12
Total liabilities 42,407 44,889
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; December 31, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively 56 56
Additional paid-in capital 27,312 27,210
Accumulated deficit (6,956) (5,958)
Accumulated other comprehensive loss (2,312) (2,459)
Treasury shares as of December 31, 2019 and December 31, 2018: 106 million ordinary shares (4,128) (4,142)
Stockholders' equity attributable to Teva shareholders 13,972 14,707
Non-controlling interests 1,091 1,087
Total equity 15,063 15,794
Total liabilities and equity $ 57,470 $ 60,683
[1] Accumulated goodwill impairment as of December 31, 2019, December 31, 2018 and January 1, 2018 was approximately $21.0 billion, $21.0 billion and $18.0 billion, respectively.